{"id":526,"date":"2019-05-20T12:25:52","date_gmt":"2019-05-20T12:25:52","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=526"},"modified":"2019-05-20T12:25:52","modified_gmt":"2019-05-20T12:25:52","slug":"nota-informativa-muh-fv-7-2019","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2019\/05\/20\/nota-informativa-muh-fv-7-2019\/","title":{"rendered":"Nota Informativa MUH (FV), 7\/2019"},"content":{"rendered":"<table class=\"tablaHome\">\n<tbody>\n<tr>\n<td><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2019\/NI_MUH_FV-7-2019-tofacitinib.htm\">Tofacitinib (\u25bcXeljanz): restricciones provisionales de uso por motivos de seguridad. Se contraindica el uso de 10 mg 2 veces al d\u00eda en pacientes con alto riesgo de embolia pulmonar<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Tofacitinib (\u25bcXeljanz): restricciones provisionales de uso por motivos de seguridad. Se contraindica el uso de 10 mg 2 veces al d\u00eda en pacientes con alto riesgo de embolia pulmonar<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-526","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=526"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/526\/revisions"}],"predecessor-version":[{"id":527,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/526\/revisions\/527"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}